GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shuttle Pharmaceuticals Holdings Inc (NAS:SHPH) » Definitions » Return-on-Tangible-Asset

Shuttle Pharmaceuticals Holdings (Shuttle Pharmaceuticals Holdings) Return-on-Tangible-Asset : -129.35% (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Shuttle Pharmaceuticals Holdings Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Shuttle Pharmaceuticals Holdings's annualized Net Income for the quarter that ended in Mar. 2024 was $-6.92 Mil. Shuttle Pharmaceuticals Holdings's average total tangible assets for the quarter that ended in Mar. 2024 was $5.35 Mil. Therefore, Shuttle Pharmaceuticals Holdings's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 was -129.35%.

The historical rank and industry rank for Shuttle Pharmaceuticals Holdings's Return-on-Tangible-Asset or its related term are showing as below:

SHPH' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -192.64   Med: -119.22   Max: -65.08
Current: -98.36

During the past 4 years, Shuttle Pharmaceuticals Holdings's highest Return-on-Tangible-Asset was -65.08%. The lowest was -192.64%. And the median was -119.22%.

SHPH's Return-on-Tangible-Asset is ranked worse than
90.48% of 1082 companies
in the Drug Manufacturers industry
Industry Median: 1.815 vs SHPH: -98.36

Shuttle Pharmaceuticals Holdings Return-on-Tangible-Asset Historical Data

The historical data trend for Shuttle Pharmaceuticals Holdings's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shuttle Pharmaceuticals Holdings Return-on-Tangible-Asset Chart

Shuttle Pharmaceuticals Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
-148.16 -192.64 -65.08 -90.28

Shuttle Pharmaceuticals Holdings Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -40.86 -90.65 -88.47 -98.50 -129.35

Competitive Comparison of Shuttle Pharmaceuticals Holdings's Return-on-Tangible-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Shuttle Pharmaceuticals Holdings's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shuttle Pharmaceuticals Holdings's Return-on-Tangible-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shuttle Pharmaceuticals Holdings's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Shuttle Pharmaceuticals Holdings's Return-on-Tangible-Asset falls into.



Shuttle Pharmaceuticals Holdings Return-on-Tangible-Asset Calculation

Shuttle Pharmaceuticals Holdings's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-6.593/( (8.654+5.952)/ 2 )
=-6.593/7.303
=-90.28 %

Shuttle Pharmaceuticals Holdings's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=-6.924/( (5.952+4.754)/ 2 )
=-6.924/5.353
=-129.35 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2024) net income data.


Shuttle Pharmaceuticals Holdings  (NAS:SHPH) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Shuttle Pharmaceuticals Holdings Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Shuttle Pharmaceuticals Holdings's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Shuttle Pharmaceuticals Holdings (Shuttle Pharmaceuticals Holdings) Business Description

Traded in Other Exchanges
N/A
Address
One Research Court, Suite 450, Rockville, MD, USA, 20850
Shuttle Pharmaceuticals Holdings Inc is a clinical stage pharmaceutical company leveraging our proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments by leveraging insights into the pillars of cancer therapy: surgery, radiation therapy, chemotherapy, and immunotherapy.
Executives
Milton Brown director SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Bette Jacobs director SHUTTLE PHARMACEUTICALS HOLDINGS, INC., 1 RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Peter Dritschilo officer: President and COO SHUTTLE PHARMACEUTICALS HOLDINGS, INC., SUITE 450, ROCKVILLE MD 20850
Anatoly Dritschilo director, 10 percent owner, officer: CEO and Chairman SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Tyvin Rich officer: Chief Medical Officer SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Mira Jung officer: Chief Scientific Officer SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Hoek Michael Vander officer: Chief Financial Officer SHUTTLE PHARMACEUTICALS HOLDINGS, INC., SUITE 450, ROCKVILLE MD 20850
Steven M Richards director SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
William Adkins director SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Joshua Schafer director SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Chris Senanayake director SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850